Incidentally Diagnosed Asymptomatic COVID-19 Does Not Increase Total Complication Risk in Total Joint Arthroplasty.

Publication date: Aug 01, 2025

Impacts of asymptomatic perioperative coronavirus disease 2019 (COVID-19) on total knee (TKA) and hip arthroplasty (THA) outcomes remains unknown. We retrospectively reviewed asymptomatically screened COVID-19 cases undergoing primary TKA or THA between 2020 and 2022. Ninety-day complications, inpatient resources, repeat hospitalizations, and functional outcomes were measured for COVID-19 patients and age- and sex-matched controls. The sample size was determined based on a priori power analysis. Statistics consisted of 2 sample t-tests or Fisher’s exact test based on variable type with α = 0. 01 to correct for multiple comparisons. Of 1914 TKA and 1424 THA patients, 20 and 28 with asymptomatic COVID-19 were compared to 75 and 105 controls, respectively. While there was no statistically significant increase in relative risk for major (TKA P = .04|THA P = .12) or thromboembolic (TKA P = .21|THA P = .04) complications, the COVID-19 group experienced mortality, ischemic stroke, pulmonary embolism, and deep vein thrombosis. There was no significant difference in admission length (TKA P = .29|THA P = .22), physical therapy (TKA P = .36|THA P = .36), labs (TKA P = .57|THA P = .82), nonhome discharge (TKA P = 1|THA P = 1), or mobility (TKA P = .18|THA P = .21). The current study suggests that, while perioperative risk of asymptomatic COVID-19 does not meet the threshold for statistical significance, arthroplasty surgeons should be aware of potential mortality and morbidity and engage in shared decision-making regarding deferral of surgery, especially for patients with other comorbidities.

Open Access PDF

Concepts Keywords
Coronavirus Coronavirus
Inpatient Joint replacement
Morbidity Postoperative complications
Ninety Preoperative screening
SARS-CoV-2
Silent infection

Semantics

Type Source Name
disease MESH COVID-19
drug DRUGBANK Tacrine
disease MESH complications
disease MESH ischemic stroke
disease MESH pulmonary embolism
disease MESH deep vein thrombosis
disease MESH morbidity
drug DRUGBANK Nonoxynol-9
disease IDO history
disease MESH Postoperative complications
disease MESH infection
disease MESH thromboembolism
disease IDO symptom
drug DRUGBANK Acetylsalicylic acid
disease MESH asymptomatic infection
drug DRUGBANK Apixaban
disease IDO process
disease MESH Comorbidity

Original Article

(Visited 6 times, 1 visits today)